Clinical Trial VICCMEL1351


A Phase 2 study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma

Principal Investigator(s)

Jeffrey Sosman


  • Protocol No. VICCMEL1351
  • Open Date: 10/17/2013
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective: To determine the overall objective response rate (RR) to vorinostat in patients with metastatic uveal melanoma harboring a GNAQ or GNA11 mutation.
  • Disease Sites: Melanoma
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Vorinostat (ZOLINZA)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01587352
  • Secondary Protocol No: 12-027



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.